Skip to content
DraconiticResearch
Search Sources API
197,787 studies31 sourcesUpdated 38 min ago
Peer-reviewedLicence not statedBMJ Open

Chidamide combined with dinutuximab beta, irinotecan and temozolomide for relapsed or refractory neuroblastoma in children: protocol for a prospective, single-centre, open-label, single-arm, phase II study in China

  • Yan Jin1,2
  • Benfu Zhong1
  • Jiarun Fu1
  • Jiayi Liu3
  • Jie Li1
  • Zhanglin Li1
  • Baocheng Gong1
  • Chaoyu Wang1
  • Shuai Man1
  • Zhongyuan Li1
  • Yun Liu1
  • Daowei Wang1
5 more authors
  • Jiaxing Yu1
  • Wenfeng Cao1
  • Qiang Zhao1
  • Xiaofan Zhu2
  • Yanna Cao1
  1. 1Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
  2. 2State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
  3. 3Department of Urology, Tianjin First Central Hospital, Tianjin, China
Open at sourceDOICite

Related

  1. Survival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts
    Holger N. Lode, Przemysław Holko, Aleksandra Wieczorek +17
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Overall survival after relapse in high-risk neuroblastoma: an adjusted indirect comparison of post-relapse dinutuximab beta, historical controls, and relapse after first-line dinutuximab beta maintenance.
    Holger N Lode, Przemysław Holko, Aleksandra Wieczorek +17
    Frontiers in oncologyPeer-reviewedCC BYFull textNeurologyEurope PMCCrossref
  3. Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
    Susanne A. Gatz, Pablo Berlanga, Gwénaël Le Teuff +36
    Clinical Cancer ResearchPeer-reviewedLicence not stated4 citedOncologyHAL
  4. Development and Optimization of 111In-Dinutuximab-IRDye800, a Dual-Modality Intraoperative Molecular Imaging Agent for Pediatric Neuroblastoma Resection
    C. Y. Yip, L. T. Rosenblum, A. Pant +13
    bioRxivPreprintCC BYFull textOncologybioRxiv
  5. Salvage nivolumab plus temozolomide associated with improved survival and clinical benefit in refractory melanoma: a retrospective cohort study
    Preethy E. Abraham, Kun Bai, Sheau-Chiann Chen +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC

Cite

BibTeXRIS
BibTeX
@article{jin2026chidamide,
  title = {{Chidamide combined with dinutuximab beta, irinotecan and temozolomide for relapsed or refractory neuroblastoma in children: protocol for a prospective, single-centre, open-label, single-arm, phase II study in China}},
  author = {Yan Jin and Benfu Zhong and Jiarun Fu and Jiayi Liu and Jie Li and Zhanglin Li and Baocheng Gong and Chaoyu Wang and Shuai Man and Zhongyuan Li and Yun Liu and Daowei Wang and Jiaxing Yu and Wenfeng Cao and Qiang Zhao and Xiaofan Zhu and Yanna Cao},
  journal = {BMJ Open},
  year = {2026},
  month = nov,
  doi = {10.1136/bmjopen-2026-123958},
  url = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-123958},
}
RIS
TY  - JOUR
TI  - Chidamide combined with dinutuximab beta, irinotecan and temozolomide for relapsed or refractory neuroblastoma in children: protocol for a prospective, single-centre, open-label, single-arm, phase II study in China
AU  - Yan Jin
AU  - Benfu Zhong
AU  - Jiarun Fu
AU  - Jiayi Liu
AU  - Jie Li
AU  - Zhanglin Li
AU  - Baocheng Gong
AU  - Chaoyu Wang
AU  - Shuai Man
AU  - Zhongyuan Li
AU  - Yun Liu
AU  - Daowei Wang
AU  - Jiaxing Yu
AU  - Wenfeng Cao
AU  - Qiang Zhao
AU  - Xiaofan Zhu
AU  - Yanna Cao
PY  - 2026
DA  - 2026/11/02
JO  - BMJ Open
DO  - 10.1136/bmjopen-2026-123958
UR  - https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-123958
SN  - 2044-6055
SN  - 2044-6055
ER  -